Medtronic received information via literature regarding clinical outcomes of surgical mitral valve repair in patients with different etiologies.All data were retrospectively collected from a single center between june 2006 and august 2017.The study population included 421 patients (predominantly male, mean age 53.1 years).Devices from multiple manufacturers were implanted in the study population.An unspecified of patients received a medtronic duran ancore annuloplasty rings (no serial numbers provided).Among all patients, 5 early in-hospital deaths (4 cardiac, 1 non-cardiac) and 14 late deaths (6 cardiac, 8 non-cardiac) occurred.For the in-hospital deaths, 4 were due to low cardiac output and 1 was due to acute renal failure.For the late deaths, 2 were due to congestive heart failure, 2 due to sudden death, 1 due to acute aortic dissection, and 1 due to myocardial infarction.No further details were provided on these deaths.Based on the available information medtronic product was not directly associated with the death(s).Among all patients adverse events included: low cardiac output syndrome, extracorporeal membrane oxygenation (ecmo) support, intra-aortic balloon pump support, new-onset atrial fibrillation, pleural effusion requiring drainage, bleeding requiring reoperation, post-operative renal failure, stroke, surgical wound infection, permanent pacemaker implantation, pulmonary complications, prolonged mechanical ventilation, moderate to severe mitral regurgitation recurrence, and endocarditis.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|